Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in March 2009 on request of the sponsor.

On 26 January 2005, orphan designation (EU/3/04/259) was granted by the European Commission to Zambon Group S.p.A, Italy, for acetylcysteine for the treatment of idiopathic pulmonary fibrosis.

Key facts

Active substance
Disease / condition
Treatment of idiopathic pulmonary fibrosis
Date of first decision
EU designation number

Sponsor's contact details

Zambon Group SpA
Via Lillo del Duca, 10
I-091 Bresso, Milan
Telephone: +39 02 66 52 41
Telefax: +39 02 66 50 14 92

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating